Shengxiang Ren

16.8k total citations · 1 hit paper
249 papers, 7.3k citations indexed

About

Shengxiang Ren is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shengxiang Ren has authored 249 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 164 papers in Pulmonary and Respiratory Medicine, 164 papers in Oncology and 58 papers in Molecular Biology. Recurrent topics in Shengxiang Ren's work include Lung Cancer Treatments and Mutations (143 papers), Lung Cancer Research Studies (80 papers) and Cancer Immunotherapy and Biomarkers (64 papers). Shengxiang Ren is often cited by papers focused on Lung Cancer Treatments and Mutations (143 papers), Lung Cancer Research Studies (80 papers) and Cancer Immunotherapy and Biomarkers (64 papers). Shengxiang Ren collaborates with scholars based in China, United States and Germany. Shengxiang Ren's co-authors include Tao Jiang, Chunxia Su, Xuefei Li, Caicun Zhou, Chao Zhao, Caicun Zhou, Caicun Zhou, Guanghui Gao, Xiaoxia Chen and Fei Zhou and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Shengxiang Ren

240 papers receiving 7.2k citations

Hit Papers

Role of IL-2 in cancer immunotherapy 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Role of IL-2 in cancer immunotherapy
    2016 404 citations Tao Jiang, Caicun Zhou et al. profile →

Peers

Shengxiang Ren
Leena Gandhi United States
Niels Reinmuth Germany
Fred R. Hirsch United States
Wendy A. Cooper Australia
Marius Ilié France
Caicun Zhou China
Ki Hyeong Lee South Korea
Niki Karachaliou Spain
Jamie E. Chaft United States
Martin Filipits Austria
Leena Gandhi United States
Shengxiang Ren
Citations per year, relative to Shengxiang Ren Shengxiang Ren (= 1×) peers Leena Gandhi

Countries citing papers authored by Shengxiang Ren

Since Specialization
Citations

This map shows the geographic impact of Shengxiang Ren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengxiang Ren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengxiang Ren more than expected).

Fields of papers citing papers by Shengxiang Ren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengxiang Ren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengxiang Ren. The network helps show where Shengxiang Ren may publish in the future.

Co-authorship network of co-authors of Shengxiang Ren

This figure shows the co-authorship network connecting the top 25 collaborators of Shengxiang Ren. A scholar is included among the top collaborators of Shengxiang Ren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengxiang Ren. Shengxiang Ren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Xian, Shengxiang Ren, Fang Liu, et al.. (2025). An antidepressant mechanism underlying the allosteric inhibition of GluN2D-incorporated NMDA receptors at GABAergic interneurons. Science Advances. 11(10). eadq0444–eadq0444. 3 indexed citations
3.
Liu, Xiaozhen, Shiqi Mao, Chuchu Shao, et al.. (2025). BIRC5 expression correlates with immunosuppressive phenotype and predicts inferior response to immunotherapy in lung adenocarcinoma. Journal of Thoracic Disease. 17(8). 5921–5935.
4.
Li, Zongjuan, Du He, Yijun Jia, et al.. (2024). SLC40A1+ macrophages contribute to the immunosuppressive tumor microenvironment in EGFR-mutated lung cancer. Science Bulletin. 70(1). 47–50. 2 indexed citations
5.
Wu, Leilei, Bo Cheng, Xiaojiang Sun, et al.. (2024). Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study. SHILAP Revista de lepidopterología. 5(3). e501–e501. 6 indexed citations
6.
Ren, Shengxiang, Jia Yu, Ai‐Sheng Xiong, et al.. (2023). P2.14-07 Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial. Journal of Thoracic Oncology. 18(11). S373–S374.
7.
Ren, Shengxiang, Yaqi Chen, Anyi Liu, et al.. (2023). PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance. Science Advances. 9(21). eade4186–eade4186. 40 indexed citations
8.
Ren, Shengxiang, Jifeng Feng, Shenglin Ma, et al.. (2023). KEYNOTE‐033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC. International Journal of Cancer. 153(3). 623–634. 12 indexed citations
9.
Ye, Lingyun, Yan Huang, Fei Zhou, et al.. (2022). Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC. Lung Cancer. 167. 25–33. 18 indexed citations
10.
Jiang, Tao, Tao Shi, Henghui Zhang, et al.. (2019). Tumor neoantigens: from basic research to clinical applications. Journal of Hematology & Oncology. 12(1). 277 indexed citations
11.
Zhao, Sha, Guanghui Gao, Wei Li, et al.. (2019). Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 130. 10–17. 121 indexed citations
12.
Jia, Yijun, Sha Zhao, Tao Jiang, et al.. (2019). Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice. Lung Cancer. 137. 85–93. 23 indexed citations
13.
Mao, Shiqi, Yanbiao Liu, Fei Zhou, et al.. (2019). P1.01-62 Association of Baseline Pulmonary Fibrosis with the Outcome of PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S383–S383. 1 indexed citations
14.
Zhao, Sha, Xuefei Li, Chao Zhao, et al.. (2018). Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Lung Cancer. 128. 33–39. 34 indexed citations
15.
Cai, Weijing, Caicun Zhou, Chunxia Su, et al.. (2017). MA15.03 The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC. Journal of Thoracic Oncology. 12(1). S429–S430. 2 indexed citations
16.
Hou, Likun, Shengxiang Ren, Bo Su, et al.. (2016). High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma. Journal of Thoracic Disease. 8(6). 1103–1111. 12 indexed citations
17.
Cao, Weijun, Manhui Li, Jianxiong Li, et al.. (2015). High Expression of Cathepsin E is Associated with the Severity of Airflow Limitation in Patients with COPD. COPD Journal of Chronic Obstructive Pulmonary Disease. 13(2). 160–166. 8 indexed citations
18.
Ren, Shengxiang, Fred R. Hirsch, Marileila Varella‐Garcia, et al.. (2014). Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(3). e21–e23. 50 indexed citations
19.
20.
Su, Chunxia, Songwen Zhou, Ling Zhang, et al.. (2010). ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Medical Oncology. 28(4). 1411–1417. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leena Gandhi Breakdown of academic impact, for papers by Niels Reinmuth Breakdown of academic impact, for papers by Fred R. Hirsch Breakdown of academic impact, for papers by Wendy A. Cooper Breakdown of academic impact, for papers by Marius Ilié Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Ki Hyeong Lee Breakdown of academic impact, for papers by Niki Karachaliou Breakdown of academic impact, for papers by Jamie E. Chaft Breakdown of academic impact, for papers by Martin Filipits
Rankless by CCL
2026